- Home
- CVR vs RNAZ Comparison
CVR vs RNAZ Comparison
Compare CVR & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVR | RNAZ |
|---|---|---|
| Founded | 1920 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 8.5M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CVR | RNAZ |
|---|---|---|
| Price | $10.24 | $8.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $280.00 |
| AVG Volume (30 Days) | 2.9K | ★ 6.5K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | N/A | ★ 54.50 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,890,260.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.35 | N/A |
| 52 Week Low | $8.15 | $0.22 |
| 52 Week High | $15.00 | $20.99 |
Technical Indicators
Market Signals| Indicator | CVR | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 31.81 | 40.90 |
| Support Level | $8.78 | $8.37 |
| Resistance Level | $14.61 | $11.62 |
| Average True Range (ATR) | 0.60 | 0.44 |
| MACD | -0.39 | -0.06 |
| Stochastic Oscillator | 14.77 | 14.28 |
Price Performance
Historical ComparisonAbout CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.